Supriya Lifesciences, the global leader in active pharmaceutical ingredient (API) manufacturing, is starting a new chapter with major leadership changes. The corporation has appointed the next generation of the Wagh family to important leadership responsibilities. The corporation has appointed Dr. Saloni Wagh as the Managing Director, Ms. Shivani Wagh as the Joint Managing Director, and Dr Satish Wagh as the Whole-Time Director and Executive Chairman. This reorganisation is a calculated step towards forward-looking innovative ideas and a consistent quality commitment for the business.

Dr. Saloni Wagh, who has over 10 years of business operations and marketing expertise, has a  Ph.D. in chemistry from Pacific University, Udaipur, and a master's degree in science from the University of Mumbai. She has been vital for the company's success, particularly in terms of sales growth. "Taking on the role of managing director is both a privilege and a major responsibility," Dr. Saloni said, clearly excited. Using our operational excellence and scientific knowledge, I see us driving innovation and value creation for our stakeholders. In a fast-changing pharmaceutical scene, we have to be adaptable and forward-looking so that our solutions satisfy global healthcare needs.

Joining Supriya Lifescience in 2014, Ms Shivani Wagh completed her Bachelor of Management Studies from Mumbai University and twin master's degrees in commerce and international business management from the University of Manchester, UK. 

Sharing her enthusiasm, Ms. Wagh said, "As Joint Managing Director, I am enthusiastic to progress our commitment to sustainability and innovation. We want to strengthen our product offerings and increase our worldwide presence by encouraging a culture of cooperation and constant development. To propel our long-term expansion goals, our attention will be on creating strategic alliances and investigating new markets.

Dr. Satish Wagh, who originally founded Supriya Lifescience, has now been appointed Executive Chairman. The company is now well-known in the pharmaceutical sector, thanks in great part to his imaginative leadership and great expertise. When considering the company's path, Dr. Satish said, "I am rather proud of Supriya Lifescience's achievements and of the solid foundation we have created." My main emphasis as Executive Chairman will be on enabling our leaders to move boldly towards a sustainable future. Maintaining our dedication to excellence and innovation, Saloni and Shivani will lead us into our new age of development with high confidence.

Effective August 1, 2024, the leadership transitions mark a turning point in Supriya Lifescience's path towards continuous innovation and expansion. The company is still committed to providing premium pharmaceutical products and increasing its position in important worldwide markets. This leadership change emphasises Supriya Lifescience's dedication to innovative ideas and strong market orientation.